Marion McCourt - 01 Jul 2024 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Signature
/s/**Marion McCourt
Issuer symbol
REGN
Transactions as of
01 Jul 2024
Transactions value $
$-767,077
Form type
4
Filing time
02 Jul 2024, 16:01:51 UTC
Previous filing
05 Jun 2024
Next filing
05 Aug 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $423,487 +1,137 +8.79% $372.46* 14,068 01 Jul 2024 Direct F1
transaction REGN Common Stock Sale $-1,190,564 -1,137 -8.08% $1047.11 12,931 01 Jul 2024 Direct F1
holding REGN Common Stock 174 01 Jul 2024 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -1,137 -50% $0.000000 1,137 01 Jul 2024 Common Stock 1,137 $372.46 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2024.
F2 The stock option award vests in four equal annual installments, commencing one year after the date of grant.